Key Stats for MRK Stock
- Past 6-Month Performance: 42%
- 52-Week Range: $73 to $125
- Valuation Model Target Price: $178
- Implied Upside: 47%
Value your favorite stocks like Merck & Co. with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Merck & Co., Inc. stock is up about 42% over the past six months, recently trading near $120 per share as investors grew more confident in the durability of its oncology franchise and the visibility of its late-stage pipeline.
Shares have climbed toward the top of their $73 to $125 52 week range as earnings momentum and improving sentiment supported the advance.
The rally has been driven primarily by resilient KEYTRUDA growth, accelerating contributions from newer products, and management’s reaffirmed long-term expansion outlook despite known headwinds.
Investors looked through roughly $2.5 billion in expected 2026 headwinds from generic competition, IRA price setting, and the restructured Koselugo agreement because core oncology and specialty launches continue to offset policy and exclusivity pressures.
This week, Merck reported Q4 revenue of $16.4 billion, up 5%, led by KEYTRUDA sales of $8.4 billion, 37% growth in WELIREG to $220 million, WINREVAIR revenue of $467 million, and OHTUVAYRE contributing $178 million, while GARDASIL declined 35% to $1 billion on weaker demand in China and Japan.
Management guided 2026 non-GAAP EPS to $5 to $5.15 and CEO Rob Davis emphasized pipeline momentum, stating the company now has “line of sight to over $70 billion of potential commercial opportunity by the mid-2030s.”
Institutional positioning has been active and broadly supportive of the advance. River Wealth Advisors increased its stake by 24.1%, Quantbot Technologies boosted its position by 125%, American Century Companies raised its holdings by 20.9%, and Harvest Portfolios Group added 8.4%, while Artisan Partners increased its position by 2.6%.
Some firms trimmed exposure, including Bedell Frazier Investment Counselling, which cut its stake by 87.3%, Banco Santander, which reduced its position by 58.3%, and Erste Asset Management, which trimmed 31.9%, yet institutional investors still own about 76.07% of the company, reinforcing strong long-term ownership behind the six-month rally.
See analysts’ growth forecasts and price targets for Merck & Co. (It’s free) >>>
Is MRK Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 5%
- Operating Margins: 38%
- Exit P/E Multiple: 16x
Merck’s outlook into 2026 remains anchored by continued global expansion of KEYTRUDA, steady uptake of WINREVAIR in pulmonary arterial hypertension, and commercialization of newer launches in cardiometabolic and respiratory.
Oncology remains the primary profit engine, while margin strength near the high 30% range reflects favorable mix, scale advantages, and disciplined expense control.
Over the next year, performance will depend on three measurable drivers: sustained KEYTRUDA volume growth across earlier-stage indications, stabilization of GARDASIL demand in China, and execution on late-stage pipeline readouts across oncology, HIV, and cardiometabolic programs.
Several Phase III milestones and regulatory decisions scheduled through 2026 could meaningfully influence how investors underwrite post-KEYTRUDA earnings durability.
Free cash flow generation continues to support dividend stability and strategic flexibility for additional business development.
At around $120 per share and trading near 16 times earnings under these assumptions, the stock appears modestly undervalued relative to its margin profile and pipeline optionality.
If oncology growth and clinical execution remain intact, Merck is positioned for steady compounding driven by earnings quality and expanding commercial opportunities rather than short-term multiple expansion.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does MRK Stock Have From Here?
Investors can estimate Merck & Co. potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See Merck & Co. true value, or any stock’s, in under 60 seconds (Free with TIKR) >>>
